Kite Pharma, Inc. 4
4 · Kite Pharma, Inc. · Filed Jul 11, 2017
Insider Transaction Report
Form 4
BUTITTA CYNTHIA M
COO and CFO
Transactions
- Sale
Common Stock
2017-07-10$101.06/sh−3,347$338,248→ 129,448 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2017-07-10−15,000→ 95,394 totalExercise: $1.35Exp: 2024-03-25→ Common Stock (15,000 underlying) - Exercise/Conversion
Common Stock
2017-07-10$1.35/sh+15,000$20,250→ 132,795 total - Sale
Common Stock
2017-07-10$102.19/sh−5,553$567,461→ 123,895 total - Sale
Common Stock
2017-07-10$102.81/sh−1,100$113,091→ 122,795 total - Sale
Common Stock
2017-07-10$105.50/sh−5,000$527,500→ 117,795 total
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2017.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.65 to $101.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.65 to $102.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.67 to $103.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F5]108,839 of the 435,394 shares originally subject to the stock option vested and became exercisable on December 15, 2014, and 9,071 shares vest monthly thereafter.